AI Bias Analysis
4 models · Takes ~15 seconds
A lung cancer drug developed in China was a highlight of ASCO but doctors want to see follow-up in a more diverse population.
Source
Stat News
Opens original article in a new tab
(MedPage Today) -- CHICAGO -- RASolute 302 trial results were hailed as a game-changing breakthrough in the treatment of pancreatic cancer. The phase III study showed that second-line daraxonrasib, an investigational oral RAS(ON) multi-selective...
Much-awaited results at ASCO show that scientists have indeed found a way to drug a "greasy ball" involved in pancreatic cancer.
By doing hormone therapy up front in prostate cancer cases, the hope was to shrink the relapse rate after surgery. Results were encouraging.
ASCO, Day 2: promising news around lung cancer, new immunotherapies, and bold words from Rick Pazdur.
